These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Peritoneal accumulation of advanced glycosylation end-products in diabetic rats on dialysis with icodextrin. Lee JH; Reddy DK; Saran R; Moore HL; Twardowski ZJ; Nolph KD; Khanna R Perit Dial Int; 2000; 20 Suppl 5():S39-47. PubMed ID: 11229611 [TBL] [Abstract][Full Text] [Related]
25. Initiating CAPD with a regimen low in glucose and glucose degradation products, with icodextrin and amino acids (NEPP) is safe and efficacious. le Poole CY; Welten AG; Weijmer MC; Valentijn RM; van Ittersum FJ; ter Wee PM Perit Dial Int; 2005 Feb; 25 Suppl 3():S64-8. PubMed ID: 16048260 [TBL] [Abstract][Full Text] [Related]
26. Binding of receptor for advanced glycation end products (RAGE) ligands is not sufficient to induce inflammatory signals: lack of activity of endotoxin-free albumin-derived advanced glycation end products. Valencia JV; Mone M; Koehne C; Rediske J; Hughes TE Diabetologia; 2004 May; 47(5):844-52. PubMed ID: 15127201 [TBL] [Abstract][Full Text] [Related]
27. Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation? Zeier M; Schwenger V; Deppisch R; Haug U; Weigel K; Bahner U; Wanner C; Schneider H; Henle T; Ritz E Kidney Int; 2003 Jan; 63(1):298-305. PubMed ID: 12472796 [TBL] [Abstract][Full Text] [Related]
28. Septic shock is associated with receptor for advanced glycation end products ligation of LPS. Yamamoto Y; Harashima A; Saito H; Tsuneyama K; Munesue S; Motoyoshi S; Han D; Watanabe T; Asano M; Takasawa S; Okamoto H; Shimura S; Karasawa T; Yonekura H; Yamamoto H J Immunol; 2011 Mar; 186(5):3248-57. PubMed ID: 21270403 [TBL] [Abstract][Full Text] [Related]
29. Circulating high-molecular-weight RAGE ligands activate pathways implicated in the development of diabetic nephropathy. Penfold SA; Coughlan MT; Patel SK; Srivastava PM; Sourris KC; Steer D; Webster DE; Thomas MC; MacIsaac RJ; Jerums G; Burrell LM; Cooper ME; Forbes JM Kidney Int; 2010 Aug; 78(3):287-95. PubMed ID: 20463655 [TBL] [Abstract][Full Text] [Related]
30. [Activation of receptor for advanced glycation end products: a mechanism for monocyte-mediated inflammation in chronic renal failure]. Hou FF; Ren H; Guo ZJ; Chen PY; Liang M; Zhang X Zhonghua Yi Xue Za Zhi; 2004 Oct; 84(19):1614-9. PubMed ID: 15569456 [TBL] [Abstract][Full Text] [Related]
31. Effect of chronic hypoxia on RAGE and its soluble forms in lungs and plasma of mice. Gopal P; Gosker HR; Theije CC; Eurlings IM; Sell DR; Monnier VM; Reynaert NL Biochim Biophys Acta; 2015 May; 1852(5):992-1000. PubMed ID: 25703138 [TBL] [Abstract][Full Text] [Related]
32. Differential effects between amphoterin and advanced glycation end products on colon cancer cells. Kuniyasu H; Chihara Y; Kondo H Int J Cancer; 2003 May; 104(6):722-7. PubMed ID: 12640679 [TBL] [Abstract][Full Text] [Related]
33. Intraperitoneal infusion of glucose-based dialysate in the rat--an animal model for the study of peritoneal advanced glycation end-products formation and effect on peritoneal transport. Zeltzer E; Klein O; Rashid G; Katz D; Korzets Z; Bernheim J Perit Dial Int; 2000; 20(6):656-61. PubMed ID: 11216555 [TBL] [Abstract][Full Text] [Related]
34. High-mobility group box-1 and its receptors contribute to proinflammatory response in the acute phase of spinal cord injury in rats. Chen KB; Uchida K; Nakajima H; Yayama T; Hirai T; Rodriguez Guerrero A; Kobayashi S; Ma WY; Liu SY; Zhu P; Baba H Spine (Phila Pa 1976); 2011 Dec; 36(25):2122-9. PubMed ID: 21343866 [TBL] [Abstract][Full Text] [Related]
35. Association of the Gly82Ser polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating levels of soluble RAGE and inflammatory markers in nondiabetic and nonobese Koreans. Jang Y; Kim JY; Kang SM; Kim JS; Chae JS; Kim OY; Koh SJ; Lee HC; Ahn CW; Song YD; Lee JH Metabolism; 2007 Feb; 56(2):199-205. PubMed ID: 17224333 [TBL] [Abstract][Full Text] [Related]
36. Impact on peritoneal membrane of use of icodextrin-based dialysis solution in peritoneal dialysis patients. Moriishi M; Kawanishi H; Tsuchiya S Adv Perit Dial; 2006; 22():24-8. PubMed ID: 16983933 [TBL] [Abstract][Full Text] [Related]
37. Upregulation of RAGE and its ligands in proliferative retinal disease. Pachydaki SI; Tari SR; Lee SE; Ma W; Tseng JJ; Sosunov AA; Cataldergirmen G; Scarmeas N; Caspersen C; Chang S; Schiff WM; Schmidt AM; Barile GR Exp Eye Res; 2006 May; 82(5):807-15. PubMed ID: 16364297 [TBL] [Abstract][Full Text] [Related]
38. "NEPP" peritoneal dialysis regimen has beneficial effects on plasma CEL and 3-DG, but not pentosidine, CML, and MGO. le Poole CY; van Ittersum FJ; Valentijn RM; Teerlink T; Lindholm B; Ter Wee PM; Schalkwijk CG Perit Dial Int; 2012; 32(1):45-54. PubMed ID: 21632443 [TBL] [Abstract][Full Text] [Related]
39. Glycation and advanced glycation end-product formation with icodextrin and dextrose. Dawnay AB; Millar DJ Perit Dial Int; 1997; 17(1):52-8. PubMed ID: 9068023 [TBL] [Abstract][Full Text] [Related]
40. Members of the receptor for advanced glycation end products axis as potential therapeutic targets in patients with lupus nephritis. Yu SL; Wong CK; Szeto CC; Li EK; Cai Z; Tam LS Lupus; 2015 Jun; 24(7):675-86. PubMed ID: 25411258 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]